KRAS and colorectal cancer: The reported results come from a limited series of patients which requires further validation, although our data show that KRAS G12V mutation is detectable in plasma of colorectal cancer patients using this ddPCR system, and could be useful as a non-invasive biomarker of drug resistance and response to treatment during disease progression.